AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT05624983 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Otoscopy
Description: presence of earwax checked by video otoscop
Study NCT05624983 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Otoscopy
Description: presence of earwax checked by video otoscop
Study NCT05624983 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Audiometry
Description: Hearing Threshold will be measured with the AD528 interacoustics
Study NCT05624983 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Audiometry
Description: Hearing Threshold will be measured with the AD528 interacoustics
Study NCT05624983 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Tympanometry
Description: Tympanic mobility will be measyred with the Titan interacoustics
Study NCT05624983 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: OTHER
Intervention: Tympanometry
Description: Tympanic mobility will be measyred with the Titan interacoustics
Study NCT03258853 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Bionic Pancreas
Description: Bionic pancreas system: The bionic pancreas is an autonomous, self-learning system that requires only the subject's weight for initialization, and then autonomously adapts insulin dosing to maintain glycemic control. The bionic pancreas uses continuous glucose monitoring as input to the controller. The bionic pancreas can be used in a bi-hormonal configuration, administering both insulin and glucagon as well as an insulin only setting.
Study NCT05815680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: metformin
Description: For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
Study NCT05815680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: digoxin
Description: For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
Study NCT05815680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: IBI362
Description: Subjects will initiate treatment with 2 mg for the first four weeks followed by 4mg for four weeks and up to a dose of 6 mg for six weeks.
Study NCT03258853 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Usual Care
Description: Subjects will remain on home insulin regimen (either insulin pump or injectable insulin). Subjects in usual care will wear a study CGM even if in typical care does not include CGM use.
Study NCT05815680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: warfarin
Description: For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
Study NCT05815680 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: atorvastatin
Description: For oral administration, given as a single dose. The first dose is given before IBI362 treatment and the second dose is given at the end of IBI362 treatment.
Study NCT06026020 — intervention group
Intervention type: OTHER
Intervention: Biological samples collection
Description: Samples of blood, faeces, saliva are collected for analysis.
Study NCT05567484 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Itraconazole
Description: 100 mg two capsules of itraconazole were given twice daily to 30 patient group A for one week per month.baseline LFTs were also monitered
Study NCT06133881 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: prilocaine
Description: intrathecal 50 mg (2.5 ml) of prilocaine 2% (Takipril, prilocaine hydrochloride 20 mg/mL, hyperbar, Sintetica) + 25 ug fentanyl (0.5 ml).
Study NCT06133881 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: bupivacaine
Description: intrathecal 10 mg (2 ml) of bupivacaine 5% (sunnypivacaine hyperbaric bupivacaine 20 mg/4ml + 25 ug fentanyl (0.5 ml
Study NCT05066126 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mixed-Presentation of Content
Description: Participants in the high-mixed presentation of content conditions will receive a social media feed that varies greatly between topics, so that each subsequent post is on a different topic. In the low-mixed presentation of content condition, participants will be shown posts on any given topic grouped together.
Study NCT05802277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Hamstring muscles function assessment
Description: Ultrasound echographic evaluation of the hamstring muscles during stretching and voluntary contractions, before and after a strenuous physical activity.
Study NCT05802277 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: Hamstring muscles function assessment
Description: Ultrasound echographic evaluation of the hamstring muscles during stretching and voluntary contractions, before and after a strenuous physical activity.
Study NCT05276128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: lipids
Description: Investigations of dose-response effects of 3 different doses of an bioactive plant based lipid consumed at breakfast, after overnight fasting. Total amounts of lipids in each test portion are 15g, and the lower doses are supplemented with a control lipid to sum upp to 15 g total lipids. A control product with15g control lipids and without active lipids is also included. The lipids are supplemented to a white wheat bread, corresponding to 50 g available starch. A White wheat bread portion without lipid supplementation is included as a well studied reference product.
Study NCT05276128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: lipids
Description: Investigations of dose-response effects of 3 different doses of an bioactive plant based lipid consumed at breakfast, after overnight fasting. Total amounts of lipids in each test portion are 15g, and the lower doses are supplemented with a control lipid to sum upp to 15 g total lipids. A control product with15g control lipids and without active lipids is also included. The lipids are supplemented to a white wheat bread, corresponding to 50 g available starch. A White wheat bread portion without lipid supplementation is included as a well studied reference product.
Study NCT05276128 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: OTHER
Intervention: lipids
Description: Investigations of dose-response effects of 3 different doses of an bioactive plant based lipid consumed at breakfast, after overnight fasting. Total amounts of lipids in each test portion are 15g, and the lower doses are supplemented with a control lipid to sum upp to 15 g total lipids. A control product with15g control lipids and without active lipids is also included. The lipids are supplemented to a white wheat bread, corresponding to 50 g available starch. A White wheat bread portion without lipid supplementation is included as a well studied reference product.
Study NCT02065323 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Standard ADT
Description: Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
Study NCT02065323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Standard ADT
Description: Standard androgen deprivation therapy with either continually dosed LHRH agonist or antagonist, or achieved via bilateral orchiectomy.
Study NCT02065323 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dovitinib
Description: Dovitinib 500 mg/day given on a five-days-on-two-days-off schedule. One cycle equals 28 days. Cycles will repeat continuously until disease progression, or removal from study for other reasons.
Study NCT05294393 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Comparator: N/S 0.9%
Description: 12 ml N/S 0.9% at the end of surgery
Study NCT05294393 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ropivacaine 10%
Description: 12 ml solution of 100mg ropivacaine at the end of surgery
Study NCT05294393 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine 10% plus magnesium sulphate 10mg/kg
Description: 12 ml solution of 100mg ropivacaine plus magnesium sulphate 10mg/kg at the end of surgery
Study NCT04617899 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Intravascular imaging
Description: Use of imaging catheter
Study NCT05504577 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Tranexamic acid injection
Description: Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
Study NCT05290662 — intervention group
Intervention type: DRUG
Intervention: oNKord®
Description: Allogeneic ex vivo-generated Natural Killer (NK) cells from CD34+ umbilical cord blood progenitor cells
Study NCT05290662 — intervention group
Intervention type: DRUG
Intervention: Cyclophosphamide/Fludarabine (Cy/Flu)
Description: Lymphodepleting conditioning regimen
Study NCT04847440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: ATI-2173
Description: ATI-2173 is a liver-targeted phosphoramidate prodrug of clevudine designed to enhance anti-HBV activity while decreasing systemic exposure to clevudine. It will be dosed as a capsule by mouth. Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
Study NCT04847440 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Viread
Description: Viread is a nucleotide analogue reverse transcriptase inhibitor used for chronic hepatitis B virus.
Study NCT04847440 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AB-729
Description: AB-729 is a potent, selective, subcutaneously administered, N-acetylgalactosamine (Ga1NAc)-conjugated small interfering ribonucleic acid (siRNA) inhibitor of HBV
Study NCT05504577 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tranexamic acid injection
Description: Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
Study NCT05236322 — intervention group
Intervention type: DEVICE
Intervention: soft tissue laser
Description: Surgical laser used in excision purpose
Study NCT05504577 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Tranexamic acid injection
Description: Tranexamic acid 1g is intravenously injected at 10 mins before tourniquet deflation. .
Study NCT05504577 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: apply the QCG
Description: apply the QCG (Quikclot Z-fold hemostatic gauze, Z-Medica, Wallingford, CT, USA) into the joint space. Compress the knee joint by elastic bandage. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
Study NCT05504577 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: apply surgical gauze
Description: apply the normal surgical gauze into the joint space. Compress the knee joint by elastic bandage. Deflate the tourniquet for 10 minutes
Study NCT04636567 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nerindocianine for injection
Description: Procedure: routine minimally invasive abdominopelvic surgery.
Study NCT06151470 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Alpha-Agonist
Description: An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Study NCT06151470 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: α-adrenergic receptor agonist
Description: An initial infusion dose of prophylactic phenylephrine (0.625 ug/kg/min) simultaneous with spinal anesthesia. The dose administered to subsequent patients varied by increments or decrements of 0.125 ug/kg/min of prophylactic phenylephrine according to the responses of previous patients according to the up-down sequential allocation.
Study NCT03814928 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caregivers eCourse
Description: Investigators will request that family/caregivers/general public watch a self-paced (60-90 minutes) online e-learning training session for recovery after hip fracture.
Study NCT05064046 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: LuCa + Health Disparity module
Description: The Health Disparity course will review disparities in the burden of lung cancer across racial/ethnic groups, discuss differences in smoking patterns and use of evidence-based smoking cessation, and describe emerging disparities in lung cancer screening. The course will also offer resources for providers to address common barriers to screening among underserved/underrepresented groups, including insurance information, transportation options, procedure time, and patient navigation assistance.~Lesson 1 of the LuCa online course addresses lung cancer screening and shared decision making.
Study NCT05064046 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: LuCa + Health Disparity module
Description: The Health Disparity course will review disparities in the burden of lung cancer across racial/ethnic groups, discuss differences in smoking patterns and use of evidence-based smoking cessation, and describe emerging disparities in lung cancer screening. The course will also offer resources for providers to address common barriers to screening among underserved/underrepresented groups, including insurance information, transportation options, procedure time, and patient navigation assistance.~Lesson 1 of the LuCa online course addresses lung cancer screening and shared decision making.
Study NCT06107543 — intervention group
Intervention type: DRUG
Intervention: Nebulized Lidocaine
Description: Before induction of anesthesia, 2% lidocaine + physiological saline was added to a nebulizer and inhaled for 3-5 minutes in the presence of 4-6 liters/minute of oxygen.
Study NCT06107543 — intervention group
Intervention type: DRUG
Intervention: Iv Lidocaine
Description: Intravenous %2 lidocaine was administered before induction of anesthesia.
Study NCT06000488 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Reflective Writing Workshop Sessions
Description: Three workshops of 75 minutes. Trained PA and/or MD student facilitators will then use prepared materials to guide each group through a series of prompts, each eliciting written reflections of varying lengths. While all participants are encouraged to reflect, write, and share their responses, participation at all levels remains optional.
Study NCT06405295 — intervention group
Intervention type: OTHER
Intervention: no intervention
Description: Observation of the prognosis of patients with different standard treatment protocols in the clinic without intervention
Study NCT05738772 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: serum sample for ELIZA
Description: Assay of AFP, AFP-L3, DCP and Soluble PDGFRβwill be done by enzyme-linked immunosorbent assay (ELISA).
Study NCT06206902 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: After preconditioning with chemotherapy, F01 will be evaluated.
Description: Biological: 0.5-3×10\^9 CAR+NK Cells, Treatment follows a lymphodepletion Drug: Fludarabine: 30 mg/m\^2 (D-5\~D-3) Drug: Cyclophosphamide: 300 mg/ m\^2 (D-5\~D-3)
Study NCT05269472 — intervention group
Intervention type: PROCEDURE
Intervention: Trigeminal Electrophysiology
Description: This study will pilot and test the feasibility of introducing electrophysiology into the routine rhizotomy procedure by including trigeminal somatosensory evoked potentials (TSEPs) and recording from electrodes at the level of the ganglion.
Study NCT05445882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bintrafusp alfa
Description: Bintrafusp alfa (1,200 mg) will be given via IV infusion every 2 weeks for up to 3 years.
Study NCT05445882 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: N-803
Description: N-803 (15 mcg/kg) subcutaneous injection will be given every 2 weeks for up to 3 years.
Study NCT05445882 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: BN-Brachyury
Description: BN-Brachyury collectively refers to the priming doses (MVA-BN-Brachyury) and the boost doses (FPV-Brachyury). MVA-BN-Brachyury subcutaneous injection will be given as 2 priming doses 2 weeks apart. FPV-Brachyury subcutaneous injection will follow MVA-BN-Brachyury injection 2 weeks later every month for 6 months total, then every 3 months until reaching 2 years. After 2 years FPV-Brachyury may be continued at 6-month dosing intervals for up to 3 years.
Study NCT05323487 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bumetanide Injection
Description: Participants in balance will present to the study site Day 0 and receive their first randomized dose of bumetanide (1.25mg, 2.5mg, 5mg, or 10mg) and undergo the bio-specimen collection protocol. They will return every 3 days, allowing 2 full days washout, to receive the other doses in random sequence.
Study NCT06283992 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Digital Navigation
Description: 1:1 educational support at the bedside about the functions of the patient portal and telehealth that can help with care transitions.
Study NCT05035095 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oral semaglutide
Description: Participants will receive a daily dose of oral semaglutide.
Study NCT05035095 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (semaglutide)
Description: Oral placebo (semaglutide) once daily. Planned treatment duration will be 68 weeks.
Study NCT05576610 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Standard preventive advice+ enzymatic mouth sprays ( Oral7 mouth spray)
Description: The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the Mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures.
Study NCT05576610 — intervention group
Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: Standard Preventive Advice + placebo mouth spray ( normal saline mouth spray )
Description: The following were the advices given face-to-face to parent and participant and a take home pamphlet was provided:~* Ensure thorough cleaning especially at the gum line and in the areas between the teeth.~* To not share toothbrushes.~* To use toothpaste containing fluoride at least 1000ppm fluoride concentration.~* To store toothbrushes apart to prevent spread of diseases through the bristles.~* To brush teeth at least twice a day, after meals and before bed.~* To brush for as long as two to three minutes.~* Parents would be advised told to supervise the participant's brushing.~Frequency of using the mouth spray would be two puffs, three times a day that is in the morning after waking up, during tea time and before sleep. A squirt is to be applied to the right/left side of the mouth on the buccal aspect and a squirt on the lingual aspect. Parents will be asked to apply the spray and to supervise children during oral hygiene procedures.
Study NCT06447571 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Trunk Rehabilitation
Description: Activating and strengthening the trunk muscles.
Study NCT06447571 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Core Stability
Description: Standard core stability fucus on lower trunk.
Study NCT05400356 — intervention group
Intervention type: PROCEDURE
Intervention: On-pump valve surgery or CABG
Description: On-pump valve surgery or coronary arterial bypass grafting
Study NCT05149612 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Heat Therapy
Description: Patients in the intervention group will be treated with hot water bags twice, 20 minutes in the morning and 20 minutes in the evening, starting four hours after the operation until discharge. In accordance with the literature, the water bag filled with 55 ± 2°C hot water will be wrapped with 2 towels. The water bag will be applied to the shoulder area while the patient is in the fawler or semi-fawler position. After 20 minutes, the hot application will be terminated. Pain and physiological parameters of the patients will be evaluated at the 0th minute, 30th minute, 4th hour, 12th hour, 24th hour and 48th hour postoperatively. At the same time, when individuals have pain, analgesics will be administered at the request of the physician.
Study NCT05073627 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dicloxacillin
Description: Healthy volunteers will take 2x500 mg dicloxacillin 3 times a day for 30 days. The investigators will measure the baseline concentration of dabigatran and dicloxacillin before start of 30 days of dicloxacillin treatment. On day 9 and 27 the investigators will measure the concentration of dicloxacillin. On day 10 and 28 the investigators will measure the concentration of dabigatran.
Study NCT06552923 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ECHO Tele-Education
Description: A common curriculum was developed that covered best practices in multidisciplinary diabetes care for the primary care setting that was guided by the ADA Clinical Care. guidelines. FQHCs attended one-hour tele-ECHO sessions twice a month for 6-months.
Study NCT06164314 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexmedetomidine
Description: In Dex group, dexmedetomidine will continue to be used during and after surgery, with a infusion of 0.4ug/kg/ h from anesthesia induction to dural closure, and then 0.08ug/kg/ h to 48 hours postoperatively.In placebo group, equivalent normal saline will be injected during operation, and the intravenous analgesia pump will not contain dexmedetomidine after operation